In the present study, IL (interleukin)-1β increased GM-CSF (granulocyte/macrophage colony-stimulating factor) expression from pulmonary A549 cells and primary HBE (human bronchial epithelial) cells. These responses were repressed by the glucocorticoid dexamethasone, allowing the use of A549 cells as a relevant model. IL-1β induced GM-CSF release into the culture medium by 6 h and in cell lysates (cytosolic) at 2 h. These effects were profoundly inhibited by dexamethasone, yet IL-1β-induced GM-CSF mRNA and unspliced nRNA (nuclear RNA; a surrogate of transcription rate) were modestly inhibited by dexamethasone at times up to 2 h. Although this indicates an effect on protein synthesis, actinomycin D chase experiments also indicated post-transcriptional repression by dexamethasone. Dexamethasone-dependent mRNA repression increased with time and was prevented by translational blockade. In addition, dexamethasone and the dissociated steroid RU24858 repressed GM-CSF release in an actinomycin D-sensitive manner, thereby implicating glucocorticoid-induced gene expression. At 2 h, IL-1β-induced expression of GM-CSF protein, but not mRNA, was sensitive to the MEK [MAPK (mitogenactivated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitors PD098059 and U0126. Although this indicates a role for the MEK/ERK pathway in GM-CSF translation, PD098059 subsequently destabilized GM-CSF mRNA. Dexamethasone and RU24858 both reduced IL-1β-induced ERK phosphorylation and increased MKP-1 (MAPK phosphatase-1) expression. Inhibition of ERK phosphorylation was reproduced by MKP-1 overexpression and prevented by MKP-1-targeting siRNA (small interfering RNA). Since MKP-1 prevented GM-CSF expression by transcriptional, posttranscriptional and translational processes, we propose that glucocorticoids induce MKP-1 expression to reduce both MEK/ERK activation and GM-CSF protein synthesis. Thus de novo gene expression, particularly of MKP-1, is involved in the repressive effects of glucocorticoids.
INTRODUCTION
In inflammation, expression of cytokines, chemokines, adhesion molecules and other inflammatory proteins drives inflammatory cell recruitment [1] . Conversely, the profound anti-inflammatory effects of glucocorticoids (also known as corticosteroids) are largely due to the repression of these same products [1] . In asthma, activation of airway structural cells by stimuli, such as IL (interleukin)-1β or TNFα (tumour necrosis factor α), leads to the expression of inflammatory proteins, including GM-CSF (granulocyte/macrophage colony-stimulating factor; CSF2) [1] . Since GM-CSF activates and promotes survival of myeloid-derived cells, including basophils, eosinophils, neutrophils, monocytes/macrophages and certain dendritic cell subsets, this factor contributes to the inflammatory influx in asthma [2] . Conversely, down-regulation of GM-CSF expression by glucocorticoids in airway epithelial cells represents a therapeutically relevant target of glucocorticoids [3] .
Transcription factors, including NF-κB (nuclear factor κB) and AP-1 (activator protein-1), are involved in the upregulation of inflammatory gene expression, such as GM-CSF [4] [5] [6] . Conversely, whereas glucocorticoids, acting via the GR (glucocorticoid receptor), exert repression on such factors (see [7] ), many reports suggest only a partial role for such repression [8] . In pulmonary epithelial cells, GM-CSF expression is highly NF-κB-dependent [9] , yet repression of NF-κB-dependent transcription and GM-CSF mRNA expression by glucocorticoids is partial [3, 10] . This suggests the existence of post-transcriptional mechanisms of repression by glucocorticoids.
A feature of many inflammatory gene mRNAs, including GM-CSF, is the presence of pentameric, AUUUA, sequences in the 3 UTR (untranslated region) [11, 12] . Such ARE (adenineand uridine-rich element)-containing sequences promote signaldependent mRNA stabilization and control gene translation [13, 14] . These motifs are also control points by which glucocorticoids promote mRNA decay [11] . Thus ZFP36 (zinc finger protein 36), known as TTP (tristetraprolin), binds AREs to negatively regulate mRNAs, such as GM-CSF [15, 16] . Since TTP expression is up-regulated by glucocorticoids, this may contribute to the post-transcriptional repression of inflammatory genes [16] [17] [18] . Alternatively, p38 MAPK (mitogen-activated protein kinase) stabilizes ARE-containing mRNAs, including GM-CSF [19, 20] . Thus induction of the dual-specificity phosphatase MKP1 (MAPK phosphatase 1; also known as DUSP1), leads to dephosphorylation and inactivation of p38 MAPK to destabilize ARE-containing mRNAs and provides a further point of regulation by glucocorticoids [21] .
These aspects of GM-CSF biology have not been extensively explored in epithelial cells relevant to airway inflammation. In the present study, we have therefore examined the control of GM-CSF expression by glucocorticoids in epithelial cells relevant to the airways.
MATERIALS AND METHODS

Cell culture and drugs
A549 cells were grown to confluence in DMEM (Dulbecco's modified Eagle's medium) (Invitrogen) supplemented with 10 % (v/v) FBS (fetal bovine serum) (Invitrogen). IL-1β (R&D Systems) was dissolved in PBS+0.1 % BSA, and dexamethasone, cycloheximide and actinomycin D (all from Sigma) were dissolved in HBSS (Hanks balanced salt solution). PD098059, U0126 (both from EMD Biosciences) and RU24858 (SanofiAventis) were dissolved in DMSO (final concentration <0.1 %). Primary HBE (human bronchial epithelial) cells, prepared from normal human lung, were cultured in bronchial epithelial cell growth medium (BioWhittaker) as described previously [22] . Prior to experiments, cells were incubated overnight in serum-free or unsupplemented medium before changing to fresh serum-free medium containing drugs.
ELISA measurement of GM-CSF in supernatants and cell lysates
GM-CSF was quantified by sandwich ELISA (DuoSet ELISA kit; R&D Systems). To assay intracellular GM-CSF protein, cells were rinsed twice with ice-cold HBSS prior to scraping into icecold HBSS. Following centrifugation at 11 000 g, cell pellets were resuspended and frozen in 1 × reporter lysis buffer (Promega) supplemented with Complete Protease inhibitor cocktail (Roche). After thawing, an equal volume of ELISA dilution buffer was added before vigorous mixing and centrifugation at 11 000 g. Samples were analysed by ELISA using standards made up in 0.5 × reporter lysis buffer. No GM-CSF was detected in the final cell wash fluid or the effluent from scraping cells, indicating that GM-CSF in the final lysates was from inside the cells or tightly associated with the cells.
Western blot analysis
Western blot analysis was performed as described previously [9] . Hybond-ECL membranes (GE Healthcare BioSciences) were incubated with the primary antisera against MKP-1 (M-18, sc-1102; Santa Cruz Biotechnology), phospho-p44/42 [ERK1/2 (extracellular-signal-regulated kinase); #9101], p44/42 (ERK1/2; #9102), phopsho-p38 MAPK (#9211) (all from Cell Signaling Technology) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [4699-9555(ST); AbD Serotec], according to the manufacturers' instructions. After washing, membranes were incubated with HRP (horseradish peroxidase)-linked secondary immunoglobulin (Dako). Immune complexes were detected using ECL (enhanced chemiluminescence; GE Healthcare BioSciences).
RNA isolation, cDNA synthesis and RT (reverse transcription)-PCR
Total RNA was isolated using the RNeasy mini kit (Qiagen), and 0.5 μg was used for RT into cDNA as described [23] . The resultant cDNA was diluted 1:4 in RNase-free water before analysis using either a validated semi-quantitative RT-PCR method or by TaqMan real-time PCR as described previously [23] . Direct comparison of these approaches produced equivalent data for IL-8 and COX-2 (cyclo-oxygenase-2) [23] . Following similar comparisons for GM-CSF (see below and Supplementary Figure S1 at http://www.BiochemJ.org/bj/427/ bj4270113add.htm), these techniques are used interchangeably. Details of PCR methods, primers and probes are in the Supplementary Materials and methods section (at http://www. BiochemJ.org/bj/427/bj4270113add.htm).
Analysis of unspliced nRNA (nuclear RNA)
Following transcriptional activation, unspliced nRNA accumulates transiently in the nucleus providing a surrogate of transcription rate [23, 24] . The TaqMan probe and primer sets were designed to cross the 5 splice junction between each intron and the preceding exon in GM-CSF, designated nGM-1A, nGM-2B and nGM-3C, for exon 1/intron A, exon 2/intron B and exon 3/intron C respectively (see Supplementary Figure S2 at http://www.BiochemJ.org/bj/427/bj4270113add.htm). Levels of unspliced GM-CSF nRNA were normalized to U6 small nRNA. Since the probe and primer sets detect both unspliced RNA and genomic DNA, the signal due to contaminating genomic DNA was assessed. RNA samples were subject to RT in both the presence and the absence of the reverse transcriptase. The amplification product in the RT-negative samples was attributed to genomic DNA contamination. Samples with >10 % genomic contamination for U6 were excluded. RNA extraction, cDNA synthesis and TaqMan real-time PCR was performed as described above. Probe and primer sequences are provided in the Supplementary Materials and methods section.
Adenoviral infection
A549 cells were grown to ∼ 70 % confluence and then incubated for 24 h with the indicated MOI (multiplicity of infection) of MKP-1-expressing adenoviral vector (Ad5-MKP-1) (Seven Hills Bioreagents) [25] , empty Ad5 vector (Null) or a GFP (green fluorescent protein)-expressing vector (Ad5-GFP) (Qbiogene). Cells were incubated in serum-free medium overnight before treatments with cytokine or drugs.
siRNA (small interfering RNA)-mediated gene silencing of MKP-1
Gene silencing using siRNA was as described previously [16] , and full details are provided in the Supplementary Materials and methods section [16] .
RESULTS
Dexamethasone represses GM-CSF production from IL-1β-treated epithelial cells
IL-1β increased GM-CSF release (P < 0.001) from confluent A549 cells to 224 + − 22 pg/ml at 6 h and 354 + − 28 pg/ml at 18 h when compared with untreated cells, which released 20-25 pg/ml. Dexamethasone inhibited this with EC 50 values of 2.2 and 3.3 nM at 6 and 18 h respectively ( Figure 1A) , which is consistent with and IL-1β (1 ng/ml), as in (A), were harvested for GM-CSF protein in the supernatants (upper panel) or intracellular GM-CSF protein in cytosolic lysates (lower panel). Results (upper panel, n = 7; lower panel, n = 6), expressed as GM-CSF release (pg/ml) (upper panel) or cytosolic GM-CSF (pg/100 μg of total protein), are means + − S.E.M. GM-CSF in the supernatants and lysates from unstimulated cells was below the detection limit for the ELISA (results not shown). (C) Primary HBE cells were treated with IL-1β in the presence or absence of dexamethasone (1 μM) before harvesting after 1, 2, 6 or 18 h for analysis of GM-CSF release. Results are from three separate donors and are means + − S.E.M. of GM-CSF release (pg/ml). Significance was tested using a paired Student's t test (B). **P < 0.01 and ***P < 0.001.
inhibition of other inflammatory mediators [23] . Inhibition by RU24858 produced EC 50 values in the 20-50 nM range, and this reflects the lower affinity for the GR [23] . Following IL-1β treatment, negligible GM-CSF was released by 2 h ( Figure 1B, upper panel) . By 6 h, this was readily detectible and, by 9 h, accumulation had reached a plateau. Release from unstimulated cells was not detected (results not shown). A maximally effective concentration of dexamethasone (1 μM) profoundly repressed GM-CSF release at all times. Intracellular GM-CSF showed a surge of production by 2 h after which accumulation decreased as the protein was secreted into the supernatant ( Figure 1B , lower panel). Dexamethasone profoundly inhibited intracellular GM-CSF accumulation at all times indicating a very rapid effect on GM-CSF synthesis.
In primary HBE cells, GM-CSF release was readily detectible at 6 and 18 h following IL-1β treatment ( Figure 1C) . At 18 h, IL-1β-treated cells (n = 7) released 571 + − 93 pg/ml. This was significantly different from unstimulated cells (82 + − 23 pg/ml), and dexamethasone (1 μM) reduced this by 61 % to 212 + − 36 pg/ml (P < 0.001). Thus A549 cells respond to IL-1β and dexamethasone in a qualitatively similar manner to primary HBE cells, validating their use to model the inhibition of GM-CSF.
Effect of dexamethasone on IL-1β-induced GM-CSF transcripts
Treatment of A549 cells with IL-1β revealed peak GM-CSF mRNA expression at 2-4 h (Supplementary Figures S1 and S2A, left-hand panel). Repression of GM-CSF mRNA by dexamethasone at 1 or 2 h was initially modest and was not significant (Figure 2A) . At 4 h, GM-CSF mRNA remained elevated, but was significantly repressed (21 % of IL-1β-treated) by dexamethasone. Although, by 6 h, IL-1β-induced mRNA was reduced, the repression by dexamethasone had increased (6.4 % of IL-1β-treated) (Figure 2A ). Thus repression elicited by dexamethasone increases with time.
To evaluate the contribution of dexamethasone-dependent repression occurring at the level of transcription, the accumulation of unspliced nuclear GM-CSF RNA was assessed ( Figure 2B ). Since unspliced nRNA appears transiently following transcriptional activation, this can be used as a surrogate for the transcription rate [23, 24] . We evaluated the presence of unspliced exon/intron junctions corresponding to exon 1/intron A (nGM-1A), exon 2/intron B (nGM-2B) and exon 3/intron C (nGM-3C) present in nuclear GM-CSF RNA (see Supplementary Figure S2 ). In untreated cells (t = 0), unspliced GM-CSF RNA levels were either close to, or indistinguishable from, the presence of genomic DNA that is inherently detected at low levels ( Figure 2B ). IL-1β rapidly elevated the accumulation of unspliced intermediates for each splice junction. This peaked at 2 h and, by 4 h, was returning towards basal levels ( Figure 2B ). By 18 h, unspliced nuclear GM-CSF RNA was indistinguishable from genomic DNA and analysis of this time was discontinued. At 1 h, there was little effect of dexamethasone on the IL-1β-induced accumulation of unspliced GM-CSF RNA. By 2 h, dexamethasone partially, but significantly, repressed accumulation of each junction. At 4 h, this was 40-50 % of IL-1β treated for the three splice junctions. Thus transcriptional repression may account for the modest repression of GM-CSF mRNA at 2 h; however, by 4 h, repression of GM-CSF mRNA was greater than can be accounted for by changes in nRNA, suggesting the existence of post-transcriptional mechanisms that repress GM-CSF mRNA expression. Likewise, at 2 h, repression of GM-CSF mRNA by dexamethasone was partial and cannot account for the repression of cytosolic GM-CSF protein. This implicates translational mechanisms of control.
In primary HBE cells, IL-1β induced GM-CSF mRNA. By 6 h, this response was declining and this continued towards 18 h ( Figure 2C , left-hand panel). As with the A549 cells, there was little or no repression of GM-CSF mRNA by dexamethasone at 1 and 2 h ( Figure 2C ). By 6 h, dexamethasone repressed GM-CSF mRNA to 37 + − 10 % of IL-1β-treated levels. Thus direct transcriptional repression may not represent the primary mode by which dexamethasone prevents GM-CSF expression.
Repression of GM-CSF mRNA by dexamethasone is prevented by cycloheximide A549 cells were treated with IL-1β for 4 h in the presence or absence of dexamethasone and/or the translational blocker cycloheximide. As reported previously [26] , GM-CSF mRNA was unaffected by cycloheximide at times up to 4 h. Dexamethasone significantly repressed IL-1β-induced GM-CSF mRNA. In the presence of actinomycin D, GM-CSF mRNA was also reduced, which is consistent with an unstable transcript [12] . However, in the presence of actinomycin D, dexamethasone elicited no further decrease in GM-CSF mRNA. Similarly, whereas the addition of cycloheximide 2 h after the IL-1β resulted in a dramatic enhancement (superinduction) of GM-CSF mRNA [26], the additional presence of dexamethasone did not affect GM-CSF mRNA. Thus dexamethasone requires ongoing transcription and translation to repress GM-CSF mRNA.
Therefore A549 cells were treated with IL-1β for 2 h to induce GM-CSF mRNA. Dexamethasone or RU24858 was then added for 1 h prior to actinomycin D to allow time for steroid-induced transcription to occur ( Figure 3B ). Using this protocol, initial rates of GM-CSF mRNA decay were very similar between the three treatments ( Figure 3B ). However, whereas IL-1β-induced GM-CSF mRNA decayed to 7.7 + − 3.1 % of the original value, with IL-1β+dexamethasone, repression was to 1.3 + − 0.3 % of the starting value. Thus dexamethasone promotes GM-CSF mRNA decay and RU24858 leads to an intermediate effect.
Differential temporal sensitivities of GM-CSF release to dexamethasone, actinomycin D and cycloheximide
The rapid cytoplasmic appearance of GM-CSF protein coincides with the kinetics of mRNA induction and indicates tight coupling between transcription and translation. Furthermore, the finding that dexamethasone profoundly represses cytosolic GM-CSF at 2 h, yet only partially inhibits mRNA production at this time, suggests translational repression. To explore the relationship between transcription, translation and repression by dexamethasone, A549 cells were treated with dexamethasone, actinomycin D or cycloheximide either at the same time as IL-1β or at times thereafter ( Figure 4A ). In all cases, supernatants were harvested 24 h after IL-1β stimulation. Simultaneous treatment with IL-1β plus actinomycin D, cycloheximide or dexamethasone resulted in no detectable GM-CSF release, confirming the requirement for transcription and translation ( Figure 4A ) [27] . Likewise, the addition of cycloheximide or dexamethasone 1 or 2 h after IL-1β resulted in low levels of GM-CSF release, despite the fact that there would have been significant cytoplasmic accumulation at 2 h. Thus intracellular GM-CSF, generated by 2 h, is, by itself, modest relative to the total produced in 24 h and ongoing GM-CSF synthesis is necessary for maximal production. Addition of cycloheximide or dexamethasone after 2 h allowed progressively more GM-CSF release and revealed that dexamethasone and cycloheximide show the same temporal efficiency of inhibition ( Figure 4A ). This is consistent with a common (translational) point of action. By contrast, actinomycin D, when added 1 h after the IL-1β, allows a response that was 27 + − 11 % of that produced by IL-1β alone. When actinomycin D was added 2 h after the IL-1β, 57 + − 12 % of the full response was apparent. Thus preventing transcription at these times does not prevent GM-CSF release and cannot explain glucocorticoiddependent repression.
Since actinomycin D, added 2 h after IL-1β, allows considerable production of GM-CSF protein, yet dexamethasone is still effective, it is possible to test the requirement for transcription in this repression. Cells were treated with IL-1β and combinations of dexamethasone, RU24858 and actinomycin D were added, either with IL-1β (results not shown) or 2 h after IL-1β, before analysis of GM-CSF release at 6 h. Addition of dexamethasone and actinomycin D with IL-1β reduced (both P < 0.001) IL-1β-induced GM-CSF release to 7.6 + − 0.8 and 1.6 + − 0.8 % respectively. RU24858 inhibited (P < 0.01) GM-CSF release to 29 + − 0.3 % of the maximum. Addition of dexamethasone or RU24858 at 2 h after IL-1β repressed (1 ng/ml) and after 6 h the supernatants were harvested for analysis of GM-CSF release. Dexamethasone (1 μM), RU24858 (10 μM) or actinomycin D (10 μg/ml) was added 2 h after IL-1β. Results (n = 6) are expressed in pg/ml and are plotted as means + − S.E.M. Statistical analyses were performed using ANOVA with a Bonferroni post-hoc test. *P < 0.05, **P < 0.01 and ***P < 0.001.
GM-CSF release to 42 + − 1.8 and 49 + − 2.0 % respectively, of the IL-1β response ( Figure 4B ). Actinomycin D had no effect on IL-1β-induced release of GM-CSF but, in combination with dexamethasone or RU24858, prevented repression.
MEK [MAPK/ERK (extracellular-signal-regulated kinase) kinase] inhibitors prevent GM-CSF synthesis, but do not initially affect mRNA expression
To explore the repressive effect(s) of glucocorticoids on GM-CSF biosynthesis, we took advantage of the observation that PD098059, a MEK1/2 inhibitor [28] , inhibits GM-CSF release ( Figure 5A ). With an EC 50 value of 6.0 μM, this was consistent with the inhibition of ERK phosphorylation, a downstream target of MEK1/2, and functional responses induced by IL-1β in A549 cells [16, 29] . Since the peak in IL-1β-induced GM-CSF mRNA occurred at 2 h, this time was used to assess the effect of PD098059 on induction of GM-CSF mRNA. Little or no effect of PD098059, at concentrations up to 50 μM, was observed on the induction of GM-CSF mRNA by IL-1β (Supplementary Figure  S6 at http://www.BiochemJ.org/bj/427/bj4270113add.htm, and Figure 5B ). The structurally distinct inhibitor U0126 shows equivalent potency for MEK1 and MEK2 [30] . U0126 inhibited GM-CSF release (EC 50 = 0.75 μM) and this coincided with the inhibition of IL-1β-induced ERK phosphorylation ( Figure 5C ) [16, 29] . Analysis of GM-CSF mRNA revealed no effect of either PD098059 (10 μM) or U0126 (1 μM) on the initial accumulation of GM-CSF mRNA at times up to 2 h ( Figure 5B ). At 4 h, and all times thereafter, IL-1β-induced GM-CSF mRNA was substantially inhibited by PD098059 and U0126. Since GM-CSF release was inhibited by MEK inhibitors, but there was little effect on GM-CSF mRNA at 2 h, we examined the effect on intracellular GM-CSF at this time ( Figure 5D ). Both PD098059 (10 μM) and U0126 (1 μM) significantly inhibited IL-1β-induced cytosolic GM-CSF protein. In addition, A549 cells were treated with IL-1β in the absence and presence of PD098059 (10 μM). After 2 h (t = 0), actinomycin D was added and RNA was harvested at times thereafter. As shown in Figure 5 (B), 2 h of IL-1β induced GM-CSF mRNA, and the presence of PD098059 did not significantly affect this (76.7 + − 12.7 % of IL-1β). Following addition of actinomycin D, IL-1β-induced GM-CSF mRNA decayed to 53.1 + − 6.6 % at 30 min and to 48.6 + − 10.5 % by 1 h, and PD098059 resulted in a significantly greater mRNA loss (29.4 + − 6.1 and 16.0 + − 3.5 % respectively; Figure 5E ). These data implicate the MEK/ERK pathway in the translation and stability of GM-CSF mRNA in A549 cells.
Primary HBE cells were treated with IL-1β in the absence or presence of 10 and 30 μM PD098059 (Table 1) . IL-1β significantly increased GM-CSF release and this was significantly abrogated in the presence of PD098059, suggesting that observations made in A549 cells apply to primary HBE cells. Statistical analysis was performed using a paired Student's t test. *P < 0.05 and **P < 0.01.
Table 1 Effect of PD098059 on GM-CSF release induced by IL-1β in HBE cells
Primary HBE cells were either not treated or treated with IL-1β (1 ng/ml) in the absence or presence of 10 or 30 μM PD098059. After 18 h, the supernatants were removed for analysis of GM-CSF release. Results (n = 7 individuals) are presented as means + − S.E.M. Multiple comparisons were made using ANOVA with a Bonferroni post-hoc test. **P < 0.01 and ***P < 0.001 compared with IL-1β alone. Figure S7 at http://www.BiochemJ.org/bj/427/bj4270113add.htm, and results not shown). However, at 30 min and 1 h after IL-1β, dexamethasone reduced the appearance of phosphorylated ERK (Figure 6A) . Although apparent at 2 h, the lower level of ERK phosphorylation made assessment unreliable. The dual-specificity phosphatase MKP-1 is glucocorticoidinducible and may target ERK [31] . In the presence of IL-1β, MKP-1 expression was induced transiently with a peak at 1 h ( Figure 6B ). Dexamethasone induced a prolonged and robust increase in MKP-1 expression. This was clearly present by 1 h with maximal levels at 6 h ( Figure 6B ). With dexamethasone+IL-1β, MKP-1 expression was enhanced relative to each treatment alone at 30 min, and at 1 and 2 h. Thus MKP-1 expression correlates with the repression of ERK phosphorylation.
To test the role of glucocorticoid-induced gene expression in the repression of phosphorylated ERK, A549 cells were treated with combinations of IL-1β, dexamethasone and RU24858 in the presence of either actinomycin D or cycloheximide ( Figure 6C ). Phosphorylated ERK was reduced by both dexamethasone and RU24858 (which also induced the expression of MKP-1) ( Figure 6C ). In the presence of actinomycin D or cycloheximide, neither dexamethasone nor RU24858 induced MKP-1 expression and there was no repression of phospho-ERK ( Figure 6C ), indicating a requirement for transcription and translation.
MKP-1 represses ERK phosphorylation and GM-CSF release induced by IL-1β
Repression of ERK phosphorylation by MKP-1 was assessed using adenoviral-mediated overexpression. Increasing MOIs of Ad5-MKP-1 increased MKP-1 expression and this correlated with the inhibition of IL-1β-induced ERK phosphorylation ( Figure 7A) . At MOIs of 100 and 300, phospho-ERK was reduced below basal levels. Equivalent effects were observed on IL-1β-induced phospho-p38 MAPK ( Figure 7A ). This represents an accepted target for MKP-1 and confirms the efficacy of the adenoviral overexpression [21] . Subsequently, cells were harvested 6 h after IL-1β treatment for analysis of GM-CSF release ( Figure 7B ). IL-1β-induced GM-CSF release was ablated by increasing MOIs of Ad5-MKP-1, but not by empty viral vector. Analysis of GM-CSF mRNA induced by IL-1β revealed a partial repression by MKP-1 at 1 and 2 h, but a more complete repression at 6 h ( Figure 7C ). This suggests that initial mechanisms of mRNA induction may be partially targeted by MKP-1, but that additional mechanisms are subsequently targeted. The fact that that MKP-1 overexpression partially reduced unspliced nuclear GM-CSF transcripts is consistent with a partial effect on IL-1β-induced transcription ( Figure 7D ). In the presence of Ad5-MKP-1, but not Ad5-GFP, GM-CSF mRNA decayed with accelerated kinetics ( Figure 7E ). Thus MKP-1 inhibits GM-CSF expression via transcriptional and posttranscriptional mechanisms. Furthermore, since repression of GM-CSF protein was near complete, yet mRNA expression was partial, these data are also consistent with translational inhibition.
To Figure S8) . A549 cells were therefore transfected with the MKP-1-targeting siRNAs or controls before treatment with dexamethasone and then IL-1β. IL-1β induced ERK phosphorylation and, despite the role of MKP-1 in normal feedback control [21] , the presence of the control or MKP-1-targeting siRNA did not modulate this response ( Figure 7F ). This is consistent with the very low level of MKP-1 induced by IL-1β at this time ( Figures 6B and  7F ). Dexamethasone reduced phospho-ERK levels and this was unaffected by control siRNA ( Figure 7F ). In the presence of MKP-1-targeting siRNAs, dexamethasone-dependent repression was reduced, confirming that dexamethasone-induced MKP-1 represses ERK phosphorylation ( Figure 7F ). The partial nature of this effect can be accounted for by the incomplete knock down of MKP-1 expression. Western blot analysis for phosphop38 MAPK confirms this result, and together these data show a role for dexamethasone-induced MKP-1 in the repression of both the ERK and p38 MAPK pathways.
DISCUSSION
In A549 and primary HBE cells, IL-1β induced GM-CSF expression and this was repressed by the anti-inflammatory glucocorticoid dexamethasone. IL-1β increased GM-CSF mRNA in both cell types and this correlated with a transient accumulation of unspliced GM-CSF nRNA. In the present study, we show that secretion of GM-CSF protein involved new gene synthesis, yet occurred rapidly with tight coupling between mRNA expression and protein production. Similarly, a rapid and striking repression by dexamethasone on GM-CSF biosynthesis is revealed. Thus GM-CSF synthesis was largely prevented at 2 h, yet mRNA repression was partial. This implicates translational repression by dexamethasone and is consistent with other studies [32] . Further evidence for translational inhibition by glucocorticoids is that dexamethasone and cycloheximide prevent GM-CSF expression with similar efficacies when added after the inducing stimulus. In respect of dexamethasone, induction of proteases, for example aminopeptidase N [33] , may enhance protein degradation, as described for GLUT2 (glucose transporter 2) and iNOS (inducible NO synthase) [34, 35] . However, if proteolysis was a major component of the overall repression, then dexamethasone should, when added after the stimulus, show greater inhibition compared with cycloheximide added at the same time. This was not the case, making translational control a rational explanation. The repressive effect of dexamethasone on GM-CSF mRNA increases with time and involves reduced GM-CSF transcription, as revealed by analysis of unspliced nRNA, and decreased mRNA stability. Inhibitors of gene expression prevented this repression, suggesting that dexamethasone induces gene synthesis to exert both transcriptional and post-transcriptional repression. In terms of post-transcriptional control, this is consistent with MKP-1 being up-regulated by dexamethasone and destabilizing AREcontaining transcripts [21] . Although GM-CSF mRNA was not reduced by inhibition of p38 MAPK (see Supplementary Figure  S9 at http://www.BiochemJ.org/bj/427/bj4270113add.htm), the most accepted target for MKP-1 [21] , we show that MKP-1 targets the ERK pathway and, along with MEK1/2 inhibition, this destabilizes GM-CSF mRNA (Figure 8 ). In respect of transcriptional repression, the idea that glucocorticoids induce gene expression to exert transcriptional repression does not fit easily with the dogma that the GR interacts with factors such as NF-κB or AP-1 to exert repression [36] . Nevertheless our present findings are consistent with studies showing that the induction of GILZ (glucocorticoid-inducible leucine zipper) represses AP-1-and NF-κB-dependent transcription [37, 38] . Likewise, the induction of MKP-1 is implicated in the repression by glucocorticoids of AP-1-and NF-κB-dependent transcription [39, 40] (Figure 8 ). Since MKP-1, like dexamethasone, may repress GM-CSF transcription, a gene that is NF-κB-and AP-1-dependent [4] [5] [6] 9] , our present results support the hypothesis that transcriptional repression exerted by glucocorticoids involves glucocorticoid-dependent gene expression.
The finding that transcriptional inhibition, by actinomycin D, was ineffective at preventing GM-CSF protein expression when added after the IL-1β stimulus, whereas dexamethasone was effective, indicates a limited role for transcriptional repression and allowed the role of glucocorticoid-induced genes to be tested. Thus dexamethasone, when added 2 h after IL-1β, represses GM-CSF protein expression. This was totally prevented by actinomycin D, indicating a requirement for gene expression. Findings that MEK inhibitors prevent GM-CSF protein accumulation, at times when mRNA expression is unaltered, suggests that the MEK/ERK pathway regulates GM-CSF translation and is consistent with established roles for this pathway [41] . The subsequent destabilization of GM-CSF mRNA may therefore be secondary to translational inhibition. However, as PD098059 prevented GM-CSF expression in primary HBE cells, a physiologically relevant mechanism that is targeted by glucocorticoids is suggested.
Since dexamethasone and the prototypical dissociated glucocorticoid RU24858 both repress ERK phosphorylation in a manner that is actinomycin D-and cycloheximide-sensitive, phosphorylates IκBα, which degrades allowing NF-κB (p50 and p65) to translocate into the nucleus. NF-κB binds to sites in the GM-CSF promoter to activate transcription. MAPK cascades are activated by upstream MAPK kinase kinases (MAP3K). These activate MAPK kinases (MAP2K) to activate MAPKs and enhance AP-1-dependent transcription. AP-1 is classically a heterodimer of proteins from the Jun and Fos family of transcriptional activators. In addition, MAPK pathways enhance transcriptional activation by NF-κB. Raf is a MAP3K, which targets the MAP2Ks MEK1/2. These target ERK to enhance GM-CSF mRNA stability and promote GM-CSF translation. After processing, mature GM-CSF is secreted outside the cell. Following cytokine stimulation, MKP-1 is transiently induced and this may exert negative feedback control on MAPKs. In the presence of anti-inflammatory glucocorticoids, MKP-1 expression is strongly induced to switch off MAPK signalling. This may reduce GM-CSF transcription and, by inhibiting ERKs, destabilize GM-CSF mRNA and reduce translation. a requirement for de novo gene synthesis is indicated. In terms of effector proteins, both dexamethasone and RU24858 induce MKP-1 expression. Furthermore, MKP-1 overexpression profoundly represses ERK phosphorylation in a manner that parallels the inhibition of phospho-p38 MAPK. The fact that siRNA targeted to MKP-1 reversed the inhibition of ERK phosphorylation by dexamethasone confirms the role of MKP-1. Therefore glucocorticoids up-regulate MKP-1 to switch off the ERK pathway at a time when GM-CSF expression is actively occurring. Thus MKP-1 reduces GM-CSF translation, promotes mRNA destabilization and may reduce transcription (Figure 8 ). However, whereas dexamethasone induces MKP-1 to reduce IL-1β-dependent activation of p38 MAPK at short times (15-20 min; results not shown), inhibition of ERK phosphorylation was observed at longer IL-1β treatment times. It is therefore possible that additional events, possibly post-translational modification, are necessary before ERK can be effectively targeted by dexamethasone-induced MKP-1. Furthermore, analysis of GM-CSF release after 6 h of IL-1β, or IL-1β+dexamethasone, revealed no obvious effect of the MKP-1-targeting siRNA (results not shown). Given the partial knock down of MKP-1 expression that is achieved, especially in the presence of both dexamethasone+IL-1β, it is possible that this is insufficient to produce functional effects. However, reversal of the dexamethasone-dependent repression of phospho-ERK argues against this. We therefore speculate that the pleiotropic nature of the repression elicited by glucocorticoids means that loss, or partial loss, of just one effector process (in this case MKP-1) is insufficient to prevent the overall repressive effect observed at the level of inflammatory gene expression [36, 42] .
In terms of new glucocorticoids or GR ligands showing antiinflammatory properties, yet reduced side-effect profiles, these data convey an important message. Although many strategies focus on reducing GR transactivation, which is associated with many side effects [36] , our present results indicate that transactivation of MKP-1 is desirable for anti-inflammatory responses. The question then arises as to why RU24858, a transactivationdefective glucocorticoid [43] , induces MKP-1 expression? Certainly, this compound shows dissociated characteristics in A549 cells [23] ; however, recent findings indicate that many, if not most, GREs (glucocorticoid-response elements) do not conform to the classical simple GRE palindrome that is optimal for binding of GR dimers [44] . Rather, composite GREs are suggested in which GR interacts with other factors to elicit transcriptional activation. Since dimerization-defective GR mutants can induce MKP-1 transcription [45] , we suggest that, although dimerizationdependent transactivation is not possible for RU24858, the ability of the GR to interact with relevant factors on the MKP-1 promoter is not substantially impaired and is sufficient for MKP-1 expression.
In conclusion, we document the repression of GM-CSF expression by glucocorticoids in primary HBE and A549 cells. We provide evidence for both transcriptional and post-transcriptional repression, but suggest that glucocorticoid-dependent gene expression is required for these to occur. We also indicate repression of GM-CSF expression at the level of protein synthesis and again show that glucocorticoid-induced genes play a key role. This concept is supported by the finding that MEK1/2 inhibitors reduce GM-CSF expression at multiple levels and that glucocorticoids target the MEK/ERK pathway via the induction of MKP-1 (Figure 8 ). On the basis of these data, we propose that GR transactivation, in this case of MKP-1, is an important component of the anti-inflammatory response to glucocorticoids. This should be considered in the design of screens for improved anti-inflammatory ligands of GR.
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Total RNA was extracted and cDNA was prepared as described in the text of the main paper. Semi-quantitative PCR was carried out as described using primers for GM-CSF (forward, 5 -ATGTTTGACCTCCAGGAGCCGA-3 ; reverse, 5 -CTGG-CTCCCAGCAGTCAAAGGG-3 ) and GAPDH (forward, 5 -CCACCCATGGCAAATTCCATGGCA-3 ; reverse, 5 -TCTA-GACGGCAGGTCAGGTCCACC-3 ) [1] . After denaturation at 94
• C for 2 min, cDNA was subjected to amplification for 18-36 cycles (dependent on the expression level of each gene in each set of samples). Amplification conditions were: 30 s denaturation at 94
• C, 30 s annealing at 58
• C (GAPDH) or 60
• C (GM-CSF), 30 s extension at 72
• C, with a final extension at 72
• C for 10 min. Amplification products were size fractionated on 1× Tris/acetate/EDTA 2 % agarose gels containing 0.5 μg/ml ethidium bromide (Sigma) and were visualized by UV illumination. Densitometric analysis of images was performed using Totallab software (Nonlinear Dynamics). In all cases, the appropriate number of amplification cycles was carefully optimized and verified against a dilution series to enable detection of amplification products within the exponential phase of the reaction (i.e. where the starting cDNA concentration is proportional to product). This approach allows relative quantification to be reliably achieved with qualitatively similar data to that obtained using real-time approaches [1] (compare Figure 2A in the main paper with Supplementary Figure S1 ).
Real-time PCR analysis was carried out using an ABI 7900HT instrument (Applied Biosystems) on 2.5 μl of cDNA using a TaqMan mastermix (Invitrogen) in a 20 μl reaction volume. Relative cDNA concentrations were obtained from a standard curve of serial dilutions of cDNA. Amplification conditions of 50
• C for 2 min, 95
• C for 10 min, 40 cycles of 95 • C for 15 s and 60
• C for 1 min were used. Analysis of GAPDH was carried out using the off-the-shelf assay 432631E (Applied Biosystems). Primers and probe for GM-CSF (M13207) were designed using Primer Express software (Applied Biosystems) (forward, 5 -AACAGTAGAAGTCATCTCAGAAATGTTTG-3 ; reverse, 5 -GCTGGCCATCATGGTCAAG-3 ; probe 5 -6FAM-CTCCAGGAGCCGACCT-MGB-3 ; where 6FAM and MGB are 6-carboxyfluorescein and minor groove binder respectively).
Design of real-time primers for the detection of unspliced nuclear GM-CSF RNA
The genomic structure for human GM-CSF (CSF2) was taken from the map viewer window in NCBI (National Center for Biotechnology Information). The accession number for the GM-CSF cDNA sequence was NM000758.2 and this corresponds to bases 39723357-39725731 of chromosome 5 of GRCh37 (Genome Reference Consortium human build 37). Amplification primers and probes were designed using Primer Express software (Applied Biosystems). Forward amplification primers were located in the exon, whereas the reverse amplification primers were designed in the corresponding intron (Supplementary Figure  S2) . In each case, the TaqMan probe was designed to cross the splice junction. Probe and primer sequences were: Gene silencing using siRNA was as described previously [2] . Cells were grown in 12-well plates to ∼60-70 % confluence, washed with serum-free DMEM and then incubated with siRNAcontaining serum-free medium at 37
• C for 24 h prior to the addition of drugs and cytokine. Transfection of siRNA was performed using Lipofectamine TM 2000 (Invitrogen). The siRNAs were mixed to a final concentration of 25 nM in 100 μl of serum-free DMEM with Lipofectamine TM 2000 (1 μl of 1 μg/μl) and incubated at room temperature for 30 min prior to adding to cells already covered with 900 μl of serumfree medium. MKP-1-targeting siRNAs were MKP-1 siRNA 1, 5 -TAGCGTCAAGACATTTGCTGA-3 (SI00374801); MKP-1 siRNA 2, 5 -CTGTACTATCCTGTAAATATA-3 (SI00374808) (both from Qiagen); and GFP (control) siRNA, 5 -GGCAAGCT-GACCCTGAAGTTC-3 (P-002048-03-20) (Dharmacon). In all cases, Western blot analysis was used to confirm knock down.
RESULTS
Analysis of GM-CSF mRNA expression following IL-1β and dexamethasone treatment by semi-quantitative RT-PCR
We have previously used semi-quantitative RT-PCR to assess changes in mRNA for various genes [1, 3, 4] . In a previous study, we used this semi-quantitative approach and then directly confirmed the data thus produced using real-time (TaqMan) PCR from the same cDNA samples [1] . Results obtained using the two approaches were essentially identical and this confirms the validity of our semi-quantitative methodology. In our semiquantitative analyses, we initially generate an 'average' sample by mixing cDNA from all of the samples in an experiment to be analysed. We then use this 'average' sample and perform PCR for various numbers of amplification cycle to allow both a minimum detection limit and the saturation limit to be established from ethidium-bromide-stained agarose gels. We then analyse all of the samples within a batch (experiment) at the number of amplification cycles where a product was first detected in the 'average' sample. Using this method, we have empirically found that the stimulated samples (in this case IL-1β) all lie within the linear range of the assay. A549 cells were treated with IL-1β (1 ng/ml) in the presence or absence of dexamethasone (1 μM). RNA was harvested at various times and subjected to semi-quantitative RT-PCR analysis for GM-CSF and GAPDH (Supplementary Figure S1) . In unstimulated cells there was no GM-CSF mRNA detected; however, following IL-1β treatment, GM-CSF mRNA became Figure S3 Cycloheximide blocks the ability of dexamethasone to repress IL-1β-induced GM-CSF mRNA A549 cells were treated with dexamethasone (Dex; 1 μM) cycloheximide (CHX; 10 μg/ml) and IL-1β (1 ng/ml), as indicated, prior to harvesting after 4 h as described in Figure 2 of the main paper. RNA was extracted and semi-quantitative RT-PCR was performed for GM-CSF and GAPDH. Ethidium-bromide-stained gels, representative of six such experiments, are shown.
readily detectible by 1 h and was generally maximal at 2 h. Steadystate mRNA levels remained high at 4 h, although typically lower than at 2 h, before declining at 6 h. The repressive effect of dexamethasone was modest at the short incubation times, but, by 4 h, resulted in pronounced reductions in GM-CSF mRNA.
Repression of GM-CSF mRNA by dexamethasone is prevented by cycloheximide
Images of ethidium-bromide-stained gels corresponding to the results presented in Figure 2 
MEK inhibitors prevent GM-CSF synthesis, but do not initially affect mRNA expression
The effect of PD098059 at concentrations up to 50 μM on the induction of GM-CSF mRNA following 2 h of IL-1β (1 ng/ml) treatment are shown in Supplementary Figure S6 . Analysis of GM-CSF and GAPDH was performed by semi-quantitative RT-PCR. At or below 10 μM PD098059, there was no effect on the induction of GM-CSF mRNA. 
Effect of glucocorticoids and IL-1β on ERK phosphorylation and MKP-1 expression
A549 cells were treated with dexamethasone (1 μM) for 1 h, prior to treatment with IL-1β (1 ng/ml) for the times indicated. After harvesting for total protein, Western blot analysis was performed for phospho-ERK (P-p42/44) and total ERK (pan p42/44). As described previously [2, 5] , basal levels of phospho-ERK were detected in untreated A549 cells (Supplementary Figure S7) . Prior incubation with dexamethasone reduced this level of basal phosphorylation. In cells stimulated with IL-1β, a rapid and transient rise in phospho-ERK was readily detected. Maximal levels occurred between 15 and 30 min post-IL-1β treatment. In the presence of dexamethasone, this initial rise in phospho-ERK was only modestly reduced; however, after 30 min, the loss of phospho-ERK appeared to be greatly accelerated in the presence of dexamethasone, such that at 30, 45 and 60 min post-IL-1β treatment there was noticeably less phospho-ERK present in the dexamethasone-treated samples.
MKP-1 represses ERK phosphorylation and GM-CSF release induced by IL-1β
The effect of siRNA directed to MKP-1 on dexamethasoneinduced MKP-1 is shown in Supplementary Figure S8 .
Effect of SB203580 on IL-1β-induced GM-CSF mRNA
The effect of SB203580 on IL-1β-induced GM-CSF mRNA was tested. As in Figure 5 (B) in the main paper, A549 cells were treated with a maximally effective concentration of SB203580 (10 μM), as previously determined by the inhibition of hsp27 (heat-shock protein 27) phosphorylation [2, 6] , prior to stimulation with IL-1β and harvesting at various times for analysis of GM-CSF mRNA.
As shown in Supplementary Figure S9 , there was no obvious effect of SB203580 on the induction of GM-CSF mRNA at any time up to 4 h. Thereafter GM-CSF mRNA appeared to be elevated in the presence of SB203580. A549 cells were pre-treated for 30 min with SB203580 (SB; 10 μM) prior to stimulation with IL-1β (1 ng/ml). Cells were harvested at the indicated times and RNA was extracted for real-time RT-PCR analysis of GM-CSF and GAPDH. Results (n = 5), as the GM-CSF/GAPDH ratio, were expressed as a percentage of IL-1β at 18 h and are plotted as means + − S.E.M.
